[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"differentiated-thyroid-cancer-dtc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:differentiated-thyroid-cancer-dtc":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100639971","phase-3-long-term-extension-study-for-participants-previously-enrolled-in-an-exelixis-sponsored-study-100639971",false,"NCT07620574","Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","Key Inclusion Criteria:\n\n* Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation\u002Fwithdrawal criteria).\n* Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.\n* Able to comply with the long-term extension study protocol as determined by the investigator.\n* Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.\n\nKey Exclusion Criteria:\n\n* Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.\n* Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.\n* Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.\n* Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).\n* Concurrent participation in any therapeutic clinical trial (other than the parent study).\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL",{"count":17,"type":18},5000,"ESTIMATED","INTERVENTIONAL",[21],"PHASE3","The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.",[24,25,26,27,28,29,30,31,32],"Cancer","Renal Cell Carcinoma (RCC)","Pancreatic Neuroendocrine Tumors (pNET)","Extra-Pancreatic NET (epNET)","Hepatocellular Carcinoma (HCC)","Differentiated Thyroid Cancer (DTC)","Non-Clear Cell Renal Cell Carcinoma (nccRCC)","Colorectal Cancer","Prostate Cancer",[25,26,27,28,29,30,31],"NOT_YET_RECRUITING","2026-05-27",{"date":37,"type":38},"2026-06-02","ACTUAL",{"date":40,"type":18},"2026-05-31",{"date":42,"type":18},"2030-05-31",{"name":44,"class":45},"Exelixis","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":19,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100634186","decision-aid-efficacy-in-low-risk-thyroid-cancer-100634186","NCT07536412","Decision Aid Efficacy in Low Risk Thyroid Cancer","Efficacy of a Patient-facing Decision Aid in Reducing Decision Anxiety and Improving Decision Readiness in Low Risk Thyroid Cancer","Inclusion Criteria:\n\n* Low-risk thyroid cancer or thyroid nodule suspicious for malignancy\n* English-speaking\n\nExclusion Criteria:\n\n* Prior consultation with surgeon regarding the thyroid nodule \u002F cancer in question\n* Cancer\u002Fnodule has high risk features (e.g. extrathyroidal extension on ultrasound)\n* History of thyroid cancer\n* History of thyroid surgery\n* Currently pregnant (per patient report)","18 Years",{"count":55,"type":18},34,[57],"NA","Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer in it, or leave the cancer in the thyroid and monitor it. Survival is similar across the 3 main treatment options. It can be difficult for patients to choose a treatment option, especially when feeling anxious about the cancer diagnosis. In this study, enrolled patients will receive a decision aid after finding out they have cancer but before meeting a surgeon. This decision aid is a pamphlet. It gives information about the treatment options and a list of questions for patients to ask their surgeons at their clinic visit. The investigators will test whether this aid changes patient decision anxiety and decision readiness.",[29,60,61],"Papillary Thyroid Microcarcinoma","Papillary Thyroid Carcinoma",[63,64,65,66,67,68,69],"decision","decision aid","thyroid cancer","papillary thyroid microcarcinoma","decision readiness","decisional conflict","overtreatment","2026-04-11",{"date":72,"type":38},"2026-04-17",{"date":74,"type":18},"2026-05-15",{"date":76,"type":18},"2029-06-15",{"name":78,"class":79},"University of Maryland, Baltimore","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":80},"100581851","the-emirates-study-100581851","NCT06855680","The EMIRATES Study","The EMIRATES Study - Development and Evaluation of Thyroid Cancer Patient Decision Aid (PDA-TC) - Pilot Study","Inclusion Criteria:\n\n* Aged over 18\n* Both genders\n* Patients who are diagnosed of low-risk well-differentiated thyroid carcinoma (papillary thyroid carcinoma or follicular carcinoma) with size of 1-4cm. This is either:\n\n  1. Diagnosed pre-operatively by fine-needle aspiration cytology (FNAC) with Thy5 grade \\[see appendix for the Thy classification\\] or\n  2. Confirmed following diagnostic hemithyroidectomy\n* Able to communicate in spoken and written English\n\nExclusion Criteria:\n\n* Patients who are diagnosed with thyroid cancer with adverse features (i.e. poor differentiated cytology or tall cell, columnar cell, Hurthle cell, and solid variant cytology)\n* Patients who are diagnosed with thyroid cancer which is multifocal, bilateral, with extrathyroidal extension, with perineural invasion or angioinvasion.\n* Patients who are diagnosed with thyroid cancer with clinically or radiologically involved nodes or distant metastases\n* Patients who are diagnosed with thyroid cancer which is of a familial disease\n* Patient who is either Pregnant or breast-feeding\n* Patient with hyper- or hypothyroidism who is a candidate for surgery\n* Patient who is concurrently diagnosed with any medullary, anaplastic, lymphoma, or parathyroid disease\n* Patients who had previous thyroidectomy for reasons other than diagnostic hemithyroidectomy for their recent cancer diagnosis.\n* Patients who are cognitively impaired or have a mental health condition and are therefore unable to give consent\n* Patient who is not able to read write and speak English",{"count":89,"type":18},15,"OBSERVATIONAL","This pilot study will take place in thyroid outpatient clinics. It will have two study arms running in consecutive order: first, a Control arm where standard care will take place without PDA-TC, then a Patient Decision Aid (PDA) arm where the PDA-TC is implemented into the clinical practice. Within each arm, eligible patients will attend two thyroid cancer outpatient clinical consultations during which the patient will make a shared decision with their clinicians regarding surgical treatment between hemithyroidectomy and total thyroidectomy. In the PDA arm, the PDA TC pamphlet will be introduced to study participants after the initial clinical consultation. The participants will be encouraged to read and digest information related to the disease and treatment options on PDA-TC before returning for their second consultation where a treatment decision will be made together with their clinicians. Participants will be asked to complete the Decisional Conflict Scale questionnaire after each consultation in both study arms. The patient will also complete a Satisfaction with Decision Scale questionnaire and a Preparation for Decision Making Scale questionnaire after the second consultation in both arms.",[29],"RECRUITING","2025-03-18",{"date":96,"type":38},"2025-03-21",{"date":98,"type":38},"2024-06-19",{"date":100,"type":18},"2025-10-14",{"name":102,"class":79},"Royal Marsden NHS Foundation Trust"]